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New drugs are needed for the treatment of relapsed acute lym-phoblastic leukemia and preclinical evaluation of the MEK inhibitor,selumetinib, has shown that this drug has excellent activity in those
leukemias with RAS pathway mutations. The proapoptotic protein, BIM is
pivotal in the induction of cell death by both selumetinib and glucocorti-
coids, suggesting the potential for synergy. Thus, combination indices for
dexamethasone and selumetinib were determined in RAS pathway-mutat-
ed acute lymphoblastic leukemia primagraft cells in vitro and were indicative
of strong synergism (combination index <0.2; n=5). Associated pharmaco-
dynamic assays were consistent with the hypothesis that the drug combi-
nation enhanced BIM upregulation over that achieved by a single drug
alone. Dosing of dexamethasone and selumetinib singly and in combina-
tion in mice engrafted with primary-derived RAS pathway-mutated
leukemia cells resulted in a marked reduction in spleen size which was sig-
nificantly greater with the drug combination. Assessment of the central
nervous system leukemia burden showed a significant reduction in the
drug-treated mice, with no detectable leukemia in those treated with the
drug combination. These data suggest that a selumetinib-dexamethasone
combination may be highly effective in RAS pathway-mutated acute lym-
phoblastic leukemia. An international phase I/II clinical trial of dexametha-
sone and selumetinib (Seludex trial) is underway in children with multiply
relapsed/refractory disease.
Introduction
Progress in the treatment of childhood acute lymphoblastic leukemia has been
exceptional and, using contemporary regimens, sustained remission is achievable
in almost 90% of children.1,2 However, the outcome of children who relapse is
much poorer and remains a frequent cause of death in children with cancer.3-5 Since
further intensification with traditional agents is often associated with significant
toxicity and limited success, new therapies are clearly needed. One promising
avenue that may deliver novel drugs comes from our previous work showing that
mutation in genes which activate the Ras/Raf/Mek/Erk pathway, such as NRAS,
KRAS, FLT3, and PTPN11, are highly prevalent in relapsed ALL and, importantly,
mutated ALL cells are differentially sensitive to the MEK inhibitor, selumetinib
(AZD6244, ARRY-142886).6-8 In contrast, RAS pathway wildtype ALL cells were
insensitive to MEK inhibition, both in vitro and in vivo.6 In the IBFMREZ2002 clinical
trial for relapsed ALL, RAS pathway mutations were associated with high-risk fea-
tures such as early relapse, central nervous system (CNS) disease and chemo-resis-
tance and a poorer overall survival was seen in patients with KRAS mutations.6 In
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the UKALLR3 trial, a poorer survival was seen in children
with NRAS mutations.7 Thus, this genetic subtype of
relapsed ALL clearly warrants exploratory therapies.
The Ras/Raf/Mek/Erk cascade regulates diverse cellular
functions, including cell proliferation, survival, differentia-
tion, angiogenesis and migration, and is deregulated in
numerous cancers, including ALL.9-13 Classic activation is
initiated by ligand binding to receptor tyrosine kinases at
the cell surface and via Ras, then Raf activates MEK1/2
which has restricted substrate specify for extracellular sig-
nal–regulated kinase 1 and 2 (Erk).  ERK is a potent kinase
with over 200 nuclear and cytoplasmic substrates includ-
ing transcription factors such as the ETS family and pro-
teins involved in the apoptotic machinery, such as the pro-
apoptotic BIM. Phosphorylation of the predominant form
of BIM (BIMEL) by ERK1/2, targets it for ubiquitination and
proteasomal degradation and may also directly hinder its
interactions with Bax14,15 and selumetinib-induced apopto-
sis is associated with BIM induction.16
Relapsed ALL is generally more drug resistant than
newly diagnosed disease and despite the use of more
intensive chemotherapeutic regimens at ALL relapse,
there are lower rates of complete remission and end-of-
induction negativity for minimal residual disease.2,3
Assessment of in vitro drug sensitivity of primary ALL sam-
ples has shown that blasts at relapse are significantly more
resistant to many of the drugs used in upfront treatment
protocols, with the highest level of drug resistance seen to
glucocorticoids.17,18 Glucocorticoids, such as dexametha-
sone, are pivotal agents in the treatment of all lymphoid
malignancies because of their ability to specifically induce
apoptosis in developing lymphocytes and induction of
pro-apoptotic BIM is key to this effect.19 Thus, BIM is a
common effector in both selumetinib- and dexametha-
sone-induced apoptosis, suggesting the potential for syn-
ergy. In addition, glucocorticoid resistance in ALL has
been associated with enhanced activation of the pathway
and its inhibition has led to glucocorticoid re-sensitiza-
tion.20-22 These effects may be more pronounced in the
context of RAS pathway-mutated ALL. We, therefore,
preclinically evaluated the combination of dexamethasone
and selumetinib in vitro and in an orthotopic mouse model
engrafted with primary-derived ALL cells and showed
pronounced drug synergism in RAS pathway-mutated
ALL. These data suggest that this drug combination may
be highly effective in the significant subgroup of patients
with this form of leukemia and has led to the Seludex trial,
an international phase I/II expansion study on the treat-
ment of relapsed/refractory RAS pathway-mutated ALL.
Methods 
Compounds and formulation
Selumetinib was kindly provided by AstraZeneca (Cheshire,
UK). For the in vitro studies, it was dissolved in dimethylsulfoxide
to a concentration of 100 mM and stored in single-use aliquots at
-20°C. Dexamethasone was purchased from Sigma-Aldrich
(Dorset, UK), dissolved in ethanol at 20 mM and stored at -20°C.
For in vivo studies, selumetinib was prepared as a suspension in
0.5% hydroxypropyl methylcellulose + 0.1% polysorbate 80. 
Patients’ samples
Primagrafts were generated in NOD SCID γ null (NSG) mice
using ALL cells from bone marrow samples of children presenting
or relapsing with ALL and accessed through the Newcastle
Haematology Biobank, after appropriate consent (reference num-
bers 2002/111 and 07/H0906). Clinical details of the patients are
given in Table 1. Mutational screening for RAS pathway muta-
tions and assessment of pathway activation by western blotting of
p-ERK was performed as previously described.8,23
In vitro drug sensitivity and synergy
Freshly harvested primagraft cells were suspended in RPMI1640
with 15% fetal bovine serum and plated out in triplicate at a den-
sity of 5x105 cells/100 μL/well into 96-well plates and treated with
a range of concentrations of dexamethasone (0.1 nM to 10 μM) or
selumetinib (1 nM to 100 μM). After 96 h, cytotoxicity was
assessed using the CellTiter 96 Aqueous One kit (Promega,
Southampton, UK). The results were averaged and expressed as a
percentage of the cytotoxicity of the control vehicle. Survival
curves were plotted and half maximal growth inhibitory values
(GI50) were calculated using GraphPad Prism software (GraphPad
software Inc., San Diego, CA, USA). Drug combination experi-
ments were analyzed for synergistic, additive, or antagonistic
effects using the combination index method developed by Chou
and Talalay.24 Briefly, primagraft cells were treated with fixed dose
ratios based on the GI50 values of each drug (x0.25, x0.5, x1, x2 and
x4) and evaluated by median effect analysis using CalcuSyn soft-
ware (Cambridge, UK). The dose-effect curve for each drug alone
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Table 1. Clinical features of patients and characterization of patient-derived xenografts.
Patient ID                               Sex            Age at diagnosis            Cytogenetics          End of induction         Ras pathway         Clonality           pERK
                                                                         (years)                                                           MRD                     mutation
L779                                                   M                              5.5                        High hyperdiploid           Intermediate              NRAS (Q61R)             Clonal             Positive
L897a                                                  M                             16.8                                 B other                         High risk                  KRAS (G12D)             Clonal             Positive
L914                                                   F                               7.3                        High hyperdiploid                Low risk                      CBL/FLT3                 Clonal             Positive
                                                                                                                                                                                                            large del/D836
L829b relapse                                   F                               3.1                        High hyperdiploid               High risk                  KRAS (G13D)             Clonal             Positive
L707c                                                  F                              16.5                                t(17;19)                        High risk              KRAS (insertion)         Clonal             Positive
LX825                                                 F                              14.7                                 B other                         High risk                      Wildtype                    N/A               Negative
L920                                                   F                               4.4                                  B other                         Low risk                       Wildtype                    N/A               Negative
L848                                                   M                              2.5                                 t(12;21)                         Low risk                       Wildtype                    N/A               Negative
aPatient suffered an on-treatment central nervous system relapse. bL829 at diagnosis was NRAS G12D. cPatient relapsed with the same KRAS mutation. B-other group: -; L897 is neg-
ative by fluorescence in situ hybridization (FISH) for ETV6-RUNX1, BCR-ABL1, MLL and TCF3-PBX1/HLF. LX825 is negative by FISH for ETV6-RUNX1, BCR-ABL1, MLL, CRLF2,
IKZF1, PAX5, IGH and  PDGFRB. ID: identity; MRD: minimal residual disease; M: male; F: female; N/A: not available.
was determined using the median-effect principle and was com-
pared to the effect achieved with a combination of the two drugs
to derive a combination index (CI) value. 
Pharmacokinetic analyses
Plasma pharmacokinetics of selumetinib and dexamethasone
were determined using non-compartmental analysis in female
CD1 mice after oral dosing. Plasma concentrations of both drugs
were measured by liquid chromatographic mass spectrometry
(API4000 LCMS/MS, Applied Biosystems, CA, USA), attached to
a Perkin Elmer chromatography system (Perkin Elmer Ltd,
Beckonsfield, UK) and calibrated using standards prepared in
blank mouse plasma. In both cases separation was performed
using a Gemini 3μC18 110A column, (50x3 mm), fitted with a 4x2
mm C18 cartridge (Phenomenex, Macclesfield, UK.
In vivo experiments
All experiments were performed under the UK Home Office
NCL-PLL60/4552. Drug efficacy studies were performed as previ-
ously described.6 Briefly, primagraft cells were injected
intrafemorally and mice were monitored for engraftment every 3-
4 weeks by tail vein bleed. Blood red cells were lysed and ana-
lyzed by flow cytometry on a BD FACSCanto II, using anti-
human CD10, CD34 and CD19 and anti-mouse CD45 antibodies.
Human leukemia cells were gated and their number expressed as
a percentage of the total number of nucleated cells. Once the level
of human leukemia cells reached >1% of total cells, mice were
randomized into groups to receive control vehicle (0.5% hydroxy -
propyl methylcellulose + 0.1% polysorbate 80) or drug treatment
(6 mice per group) with dexamethasone, selumetinib or both,
administered by oral gavage. Selumetinib was dosed at 25 mg/kg
bid, while the dexamethasone dose varied in each study. Tumor
burden was monitored weekly by flow cytometry.
Pharmacodynamic studies were performed in highly engrafted
mice which were dosed for 72 h. Spleens were removed following
euthanasia and assessed by flow cytometry to confirm an engraft-
ment of >85%. Cells were lysed and analyzed by western blotting
for levels of p-ERK, ERK2, BIM, MCL1 and a-tubulin, as described
above.
Additional details of the study methods are provided in the
Online Supplementary Material.
Results
The combination of selumetinib and dexamethasone
show synergy in vitro in RAS pathway-mutated acute
lymphoblastic leukemia and is associated with
enhanced induction of BIM
To investigate possible synergism, the R3F9 cell line and
primagraft ALL cells, with and without Ras pathway
mutations (n=8), were treated with dexamethasone,
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Figure 1. The combination of selumetinib and dexamethasone shows synergy in vitro in RAS pathway-mutated acute lymphoblastic leukemia and is associated
with enhanced levels of BIM. (A) Viability curves of Ras pathway-mutant acute lymphoblastic leukemia (ALL) cells (L829R) with individual drugs and the selume-
tinib/dexamethasone drug combination. (B) Histogram of combination indices for the selumetinib/dexamethasone combination in wildtype and Ras pathway-mutant
ALL cells; mutated genes are shown in brackets. (C) Western analyses of ALL cells (L829R) treated with control vehicle (CV) or GI50 values of selumetinib (10 μM)
and dexamethasone (10 μM), singly and in combination. (D) A representative median effect curve (data shown are from L897) after simultaneous drug dosing and
with each drug added 24 h prior to the partner drug, followed by a further 72 h incubation. CV: control vehicle; Sel: selumetinib; Dex: dexamethasone; CI: combination
index. 
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selumetinib and the drug combination at 0.25x, 0.5x, 1x,
2x and 4x their respective GI50 concentrations and viability
data were evaluated by median effect analysis. The CI for
all RAS pathway-mutated samples were indicative of
strong synergy with a mean of 0.1 (range, 0.02-0.15)
(Figure 1A,B and Online Supplementary Figure S1).
Synergism was not observed in ALL primagraft cells with-
out RAS pathway activation (CI >1.2). Mechanistic assess-
ments were performed with the GI50 concentration of both
drugs for 24 h. As expected, ALL cells treated with selume-
tinib resulted in almost complete inhibition of ERK phos-
phorylation and downregulation of MCL1 levels.
Dexamethasone treatment also downregulated pERK lev-
els. Treatment with dexamethasone or selumetinib was
associated with increased levels of BIM which were fur-
ther enhanced with the drug combination. A representa-
tive western blot and a histogram of the combined densit-
ometry values (n=4 patient-derived xenografts) are shown
in Figure 1C and Online Supplementary Figure S2A. The
apoptotic marker, cleaved PARP, was enhanced with the
drug combination in some, but not all, patient-derived
xenograft samples at this time point (Online Supplementary
Figure S2B). While the loss in cell viability in non-dividing
patient-derived xenograft ALL cells must be due to
increased cell death, we also showed enhanced apoptosis
with the drug combination for the NRAS-mutated R3F9
cell line (Online Supplementary Figure S2C,D), an effect
reduced by BIM knockdown (Online Supplementary Figure
S2E,F). There were similar levels of induction of the glu-
cocorticoid receptor target gene, GILZ, in cells treated
with both dexamethasone and with the drug combination
suggesting that enhanced glucocorticoid receptor tran-
scriptional activity is not a component of the synergism
(Online Supplementary Figure S3). Synergism between
selumetinib and other drugs for example, gemcitabine, is
highly schedule dependent and sequential rather than
simultaneous dosing appears optimal.25 Thus, we assessed
synergism in primagraft ALL cells dosed simultaneously or
with only selumetinib or dexamethasone for 24 h fol-
lowed by both drugs for an additional 72 h, prior to cell
viability assessments. We saw similar synergism across all
experimental parameters (Figure 1D) and thus we selected
simultaneous drug administration in subsequent in vivo
studies.  
Pharmacokinetic studies to define a clinically relevant
oral dose and exclude drug-drug interactions
To determine the optimal oral dose of dexamethasone
that will achieve clinically relevant serum levels, pharma-
cokinetic studies were performed in CD1 mice. Mice
(n=27) were dosed with 0.5, 1 and 5 mg/kg dexametha-
sone by oral gavage. Blood samples were taken after 15
min, 30 min, 1 h, 3 h, 6 h and 24 h and serum dexametha-
sone levels were analyzed (Online Supplementary Figure
S4A). A Tmax of 60 min was observed, with Cmax values of
48.9, 94.7 and 766.5 ng/mL following the 0.5, 1 and 5
mg/kg doses, respectively. Given the reported Cmax average
of 40-90 ng/mL in recent UK and American ALL trials, 1
mg/kg was deemed the most appropriate dose level.26,27
Dexamethasone can induce cytochrome P450 forms,
including CYP3A4, the principal isoform responsible for
selumetinib oxidative metabolism; we therefore per-
formed selumetinib pharmacokinetic analyses, following
administration of the drug alone (25 mg/kg) and after co-
administration with 1 mg/kg dexamethasone (Online
Supplementary Figure S4B,C). A Tmax of 60 min was
observed, with Cmax values for selumetinib of 4.74 μg/mL
compared to 5.49 μg/mL, respectively (P>0.05, Student t
test). Other parameters were also similar (Online
Supplementary Figure S4C), indicative of no drug-drug
interaction (P>0.05 for all).   
Selumetinib and dexamethasone show synergy in vivo
and clear central nervous system disease
The drug combination was evaluated in vivo and its
effects compared to those of single drugs and control vehi-
cle  in primagrafts derived from diagnostic ALL (NRAS
Q61R and KRAS G12D) and relapse (KRAS G13D) samples.
Scheduling and dosing, by oral gavage, are shown in Figure
2A-G. Given the significant weight loss (>20%) associated
with dexamethasone, dosing could not be prolonged, even
when the dose was lowered from 1 mg/kg bid to 0.25
mg/kg sid. There was no additional toxicity observed in
mice given the drug combination. Nevertheless, at the end
of the dosing period, there was a significant reduction in
spleen size with selumetinib or dexamethasone alone but a
statistically greater reduction in mice given the drug combi-
nation, with spleen weights approaching those of healthy
mice (P<0.001) (combined data are shown in Figure 2G). In
addition, brains were assessed for the depth of leukemia
infiltration in the leptomeninges. For mice engrafted with
L897 and L779 primagraft cells, there was a significant
reduction in leukemic infiltration in drug-treated mice, with
a mean and standard deviation of 66.3 μ ± 100.6 for animals
given the control vehicle, compared to 3.1 μ ± 12.5 for those
treated with dexamethasone and 5.37 μ ± 21.475 for those
treated with selumetinib (Online Supplementary Figure S5A).
Mice treated with the drug combination showed no
leukemic infiltration (P<0.05 for all by the Student t test).
For L779, there was demonstrable CNS disease once
peripheral ALL exceeded 1% i.e. pre-dosing (Online
Supplementary Figure S5B). Clearance of CNS disease in mice
engrafted with L829R cells was unevaluable because of
minimal CNS leukemia in both control and drug-treated
mice. The results of the pharmacodynamic assessment of
engrafted spleens after short-term dosing were consistent
with observations in vitro; inhibition of ERK phosphoryla-
tion and lower MCL1 levels associated with selumetinib
dosing, similar induction of GILZ with dexamethasone dos-
ing, and modest enhancement of BIM levels with the drug
combination (Figure 3A-D). Annexin V binding in circulat-
ing ALL cells, as detected by multi-parameter flow cytome-
try, increased at both 24 h and 48 h in all drug-treated mice
and was highest for those given the drug combination
(Figure 3E).
Discussion
Selumetinib is a potent, selective, allosteric inhibitor of
MEK1/2 with demonstrated anti-tumor activity and a
favorable toxicity profile. It has progressed to phase III
clinical trials for several types of adult solid cancers.28-30 In
the pediatric setting, selumetinib has recently undergone
phase I clinic testing as a monotherapy in children with
BRAF-driven recurrent/refractory pediatric low-grade
glioma which defined a maximum tolerated dose of 25
mg/m2/dose bid.31 Sustained responses (1 complete, 7 par-
tial) were observed in some children and selumetinib was
well tolerated, with the most common toxicity being rash.
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Figure 2. Selumetinib and dexamethasone show synergy in vivo in RAS pathway-
mutated acute lymphoblastic leukemia. (A-F) In vivo drug efficacy studies of single
drugs and their combination in RAS pathway mutated-acute lymphoblastic leukemia
(ALL) showing dose scheduling and peripheral blood monitoring before and during
dosing and spleen weights at the end of dosing for mice with L779-NRAS (A and B,
respectively),  L897-KRAS (C and D) and L829 relapse- KRAS (E and F) ALL. For
L779, mice were dosed with selumetinib at 25 mg/kg and dexamethasone at 1
mg/kg twice daily and then once daily after a recovery period. For L897, the dosage
of selumetinib was 25 mg/kg and that of dexamethasone 0.5 mg/kg (bid), with the
dexamethasone being increased to 1 mg/kg (sid) following a recovery period. For
L829R, selumetinib was dosed at 25 mg/kg (bid) and dexamethasone at 0.25
mg/kg (sid). (G) The mean and standard deviation are shown for combined spleen
weight data for all three efficacy experiments (one-way analysis of variance with the
Tukey multiple comparison test, ***P<0.001, ****P<0.0001;  n=17 mice treated
with control vehicle, n=17 treated with selumetinib, n=15 treated with dexametha-
sone and n=14 treated with the combination. CV: control vehicle; Sel: selumetinib;
Dex: dexamethasone.
C D
E F
G
A B
Glucocorticoids and selumetinib in RAS pathway-mutated ALL
haematologica | 2019; 104(9) 1809
Figure 3. Pharmacodynamic analyses in acute lymphoblastic leukemia cells after drug dosing in vivo support in vitro data. (A,B) Western blot analyses of spleen
cells from mice engrafted with RAS pathway-mutant acute lymphoblastic leukemia cells 72 h after dosing: L779; NRAS; 25 mg/kg selumetinib and 1 mg/kg dexam-
ethasone bid (A) and L897; KRAS; 25 mg/kg selumetinib and 0.5 mg/kg dexamethasone bid (B). (C) Histograms of densitometry from western blot analyses, showing
mean ± standard error of mean (SEM) (3-4 mice per treatment) [one-way analysis of variance (ANOVA) with the Tukey multiple comparison test, *P<0.05, **P<0.01].
(D) Relative expression of GILZ mRNA (mean and SEM) in treated mice compared to those given the control vehicle, as quantified by real-time polymerase chain
reaction analysis in all three patient-derived xenograft experiments, again after 72 h dosing (ANOVA as before **P<0.01; ns, not significant. (E) Histograms of annex-
in V-positive ALL cells (mean ± SEM) determined by flow cytometric analyses of peripheral blood at 24 h and 48 h  after dosing (2 mice per group). CV: control vehicle;
Sel: selumetinib; Dex: dexamethasone.
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In addition, a phase I trial of selumetinib in children with
neurofibromatosis type 1 and inoperable plexiform neu-
rofibromas showed partial responses in 17 of 24 children
(71%) and no excess toxicity was reported.32
While we have previously shown preclinical activity of
selumetinib in ALL, this drug, like other MEK inhibitors, is
likely to show maximal therapeutic benefit in combina-
tion. Indeed, in phase III clinical trials for advanced non-
small-cell lung cancer and uveal melanoma, selumetinib
has been evaluated in combination with docetaxel and
dacarbazine, respectively.33 In this current study, we show
significant synergy of selumetinib with the synthetic glu-
cocorticoid dexamethasone in vitro and in an orthotopic
mouse model engrafted with RAS pathway-activated pri-
mary-derived ALL cells. Importantly, we demonstrate this
across a range of cytogenetic subgroups, including high
hyperdiploidy, B-other, t(17;19) and t(1;19) ALL.
Pharmacokinetic data showed clinically relevant drug lev-
els and optimal scheduling and in vivo pharmacodynamic
analyses confirmed an impact on drug targets and apopto-
sis. Mechanistically, the synergism was associated with
enhanced induction of the pro-apoptotic protein, BIM,
and decreases in the anti-apoptotic BH3-only protein,
MCL1. BIM is a BH3-only protein that binds to anti-apop-
totic BCL2 family members, including MCL1 and BCL2,
to liberate and directly activate bax and bak, which then
elicit caspase-dependent apoptosis. BIM is an effector pro-
tein in both glucocorticoid and MEK inhibitor responses
and reducing pERK activity enhances BIM levels as well as
decreasing MCL1 protein levels by increasing its
turnover.34 Therefore, we propose that the drug combina-
tion enables BIM to inhibit anti-apoptotic BH3-only pro-
teins more completely and directly activate BAX and BAK.
Others have reported a direct effect of MEK inhibition on
glucocorticoid receptor transcriptional activity which may
also contribute to the synergism, but this did not appear
significant in our experiments at the time point chosen.22
Epigenetic regulation of the BIM locus due to acetylation
has been described in a subgroup of glucocorticoid-resis-
tant ALL and is associated with BIM under-expression.
Such individuals may be expected to have a suboptimal
response to the selumetinib/dexamethasone drug combi-
nation.35 However, the incidence of acetylated BIM in the
relapsed setting and in the context of RAS pathway muta-
tions has not been described to date. Our synergism data
are supported by a study by Jones et al., who used an inte-
grated approach to understand glucocorticoid resistance
and relapse and identified MAPK pathways as a contribu-
tory factor.22 In this study, knockdown of MEK2 or MEK
inhibition enhanced responses not only to glucocorticoids
but also to other chemotherapeutics and was not depend-
ent on the presence of RAS pathway mutations, a finding
suggestive of activation of the pathway through alterna-
tive routes. We have previously shown an excellent corre-
lation between pERK activation and the presence of RAS
pathway mutations, although we too noted some rare
exceptions which in our study were in part explained by
the presence of chromosomal translocations, including the
Philadelphia chromosome and 11q23.6
Drug synergies have also been shown for MEK inhibitors
with both traditional chemotherapeutics such as gemc-
itabine and targeted agents including PI3K/AKT
inhibitors36,37 and the BCL-XL inhibitor, navitoclax
(ABT263).38 Inhibiting the other effector pathways of RAS
is clearly a rational strategy; however, while we have
observed synergism of MEK and AKT inhibition in RAS
pathway-mutated ALL in vitro, the synergism was consid-
erably weaker than that observed with dexamethasone
(unpublished observations). In solid cancers, increased lev-
els of BIM protein are also observed with MEK inhibition,
but the protein is inactive due to sequestration by high lev-
els of BCL-XL. In the presence of navitoclax, BIM is
released, triggering an apoptotic response.38
We have previously reported a reduction of CNS
leukemia in selumetinib-treated mice and now confirm
this in additional primagraft samples and show complete
absence of leukemic infiltration in the leptomeninges of
mice treated with the selumetinib/dexamethasone drug
combination.6 The identification of CNS disease in mice
with similar levels of ALL engraftment prior to drug dosing
suggests that the drug combination completely eradicated
the leukemia in situ. This is a highly significant finding
given the association of RAS pathway mutations and CNS
disease at relapse that we previously reported in the IBFM-
REZ2002 clinical trial and the fact that in contemporary
regimens, the proportion of CNS relapses is increasing.39
A key question, relevant to MEK inhibitor therapy, is
whether Ras pathway mutations are initiating events in
ALL or secondary, cooperating genetic events and there is
evidence for both.13 However, for targeted therapies to be
successful, the target is ideally present on all tumor cells
and we and others have reported that mutations can be
subclonal, particularly at diagnosis, and can be gained or
lost at relapse.6,40-42 Importantly, we have also shown that
mutations at relapse are in the major ALL clone, are often
selected from a minor subclone at diagnosis and that
apparent ‘loss’ of a Ras pathway mutation can be ‘replace-
ment’ of one for another.6,8,43 This suggests a dependence
on the pathway that can be exploited by MEK inhibition
and, as we show here, is enhanced with co-exposure to
dexamethasone.
Based on these promising data, an international phase
I/II clinical trial of oral dexamethasone and selumetinib
(Seludex) is underway in RAS pathway-mutated, multiply
relapsed/refractory ALL. A parallel, national study in adult
disease at first relapse is also ongoing, since the prevalence
of RAS pathway mutations and association with poor
prognosis has also been noted.44 One relevant observation
from selumetinib and other Mek inhibitor trials is that the
most common toxicity is inflammatory rash. In severe
cases, the recommended treatment is oral glucocorticoids
and no adverse effects of drug co-administration have
been reported.45 Thus, if efficacy is seen in the proposed
clinical trials, selumetinib and other Mek inhibitors may
be a much needed novel therapy for a substantial number
of children with high-risk, relapsed disease. There may
also be a role for the drug combination in the upfront
treatment of RAS-driven, high-risk ALL, to avert relapse.
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